Edition:
United States

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

39.58USD
12:07pm EDT
Change (% chg)

$0.83 (+2.14%)
Prev Close
$38.75
Open
$38.86
Day's High
$39.58
Day's Low
$38.79
Volume
94,370
Avg. Vol
267,956
52-wk High
$41.57
52-wk Low
$24.45

Select another date:

Mon, Apr 30 2018

BRIEF-Medicines Co Says CEO Clive A. Meanwell's 2017 Total Compensation Was $7.6 Million

* MEDICINES CO SAYS CEO CLIVE A. MEANWELL'S 2017 TOTAL COMPENSATION WAS $7.6 MILLION VERSUS $6.7 MILLION IN 2016 – SEC FILING Source : https://bit.ly/2KsU3bs Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-The Medicines Co Reports Q1 GAAP Loss Per Share $1.14 From Continuing Operations

* Q1 ADJUSTED NON-GAAP LOSS PER SHARE $0.76 FROM CONTINUING OPERATIONS

BRIEF-The Medicines Company Announces Chief Financial Officer Transition

* THE MEDICINES COMPANY ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION

BRIEF-Medicines Co Says Board Appointed Christopher Visioli As CFO

* MEDICINES - ON MARCH 21, BOARD APPOINTED CHRISTOPHER VISIOLI CFO AND TREASURER OF COMPANY, EFFECTIVE IMMEDIATELY

Medicines Company cuts board size, activist Denner to get more control

Medicines Company on Thursday said it was cutting the number of directors on its board, a move that could give billionaire investor Alex Denner greater control.

Medicines Company cuts board size, activist Denner to get more control

March 1 Medicines Company on Thursday said it was cutting the number of directors on its board, a move that could give billionaire investor Alex Denner greater control.

BRIEF-The Medicines Company Appoints Sarah Schlesinger To Its Board Of Directors

* THE MEDICINES COMPANY APPOINTS SARAH SCHLESINGER TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-The Medicines Q4 GAAP Loss Per Share $2.19 From Continuing Operations

* THE MEDICINES COMPANY REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 BUSINESS AND FINANCIAL RESULTS

BRIEF-The Medicines Company Reaches Enrollment Target For Orion-9 Ahead Of Schedule

* THE MEDICINES COMPANY REACHES ENROLLMENT TARGET FOR ORION-9 AHEAD OF SCHEDULE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Select another date: